Cart
sales@molnova.com
BMS-488043
CAS No. 452296-83-2
BMS-488043( —— )
Catalog No. M34526 CAS No. 452296-83-2
BMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 323 | In Stock |
|
| 10MG | 485 | In Stock |
|
| 25MG | 787 | In Stock |
|
| 50MG | 1070 | In Stock |
|
| 100MG | 1442 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2762 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBMS-488043
-
NoteResearch use only, not for human use.
-
Brief DescriptionBMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.
-
DescriptionBMS-488043 is a novel and unique oral small molecule HIV fusion inhibitor that inhibits the attachment of Human Immunodeficiency Virus type 1 (HIV-1) to CD4(+) lymphocytes.BMS-488043 is used for the treatment of immune disorders, infections, and genitourinary disorders, and can be used in the study of HIV infect
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
RecptorHIV Protease
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number452296-83-2
-
Formula Weight422.43
-
Molecular FormulaC22H22N4O5
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C(=O)N1CCN(C(=O)C2=CC=CC=C2)CC1)(=O)C=3C=4C(=C(OC)N=CC4OC)NC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Nevirapine
A potent and specific non-nucleoside inhibitor (NNRTI) of HIV-1 reverse transcriptase with Ki of 0.2 uM.
-
Isoxanthohumol
Isoxanthohumol shows an antiviral activity towards herpes viruses (HSV1 and HSV2) and bovine viral diarrhea virus (BVDV).
-
1E7-03
1E7-03 is a small molecule targeting the RVxF interacting site on PP1, inhibits HIV-1, Ebolavirus (EBOV), and Venezuelan equine encephalitis virus (VEEV, EC50=0.6 uM).
